David E Redlick Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Redlick ISEE stock SEC Form 4 insiders trading

David has made over 1 trades of the IVERIC bio Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently David sold 700 units of ISEE stock worth $1,764 on 13 June 2017.

The largest trade David's ever made was selling 700 units of IVERIC bio Inc stock on 13 June 2017 worth over $1,764. On average, David trades about 140 units every 0 days since 2016. As of 13 June 2017 David still owns at least 1,050 units of IVERIC bio Inc stock.

You can see the complete history of David Redlick stock trades at the bottom of the page.

What's David Redlick's mailing address?

David's mailing address filed with the SEC is One Penn Plaza Suite 1924 New York, NY 10119 Pennsylvania Plaza #1924, New York, NY 10119, USA.

Insiders trading at IVERIC bio Inc

Over the last 5 years, insiders at IVERIC bio Inc have traded over $8,677,595 worth of IVERIC bio Inc stock and bought 130,569 units worth $624,325 . The most active insiders traders include Glenn Sblendorio, Venture Capital Iv, L.P.Ver... a Keith Westby. On average, IVERIC bio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $848,338. The most recent stock trade was executed by Keith Westby on 3 July 2023, trading 20,000 units of ISEE stock currently worth $58,800.

What does IVERIC bio Inc do?

we are a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (amd).

IVERIC bio Inc executives and stock owners

IVERIC bio Inc executives and other stock owners filed with the SEC include:

• Glenn Sblendorio,
  President, Chief Executive Officer, Director
• David Guyer,
  Executive Chairman of the Board
• Anthony S. Gibney,
  Exec. VP and Chief Bus. & Strategy Officer
• David Carroll,
  Chief Financial Officer, Senior Vice President, Treasurer
• Keith Westby,
  Chief Operating Officer, Senior Vice President
• Glenn P. Sblendorio M.B.A.,
  CEO & Director
• Dr. Pravin U. Dugel M.D.,
  Pres
• David F. Carroll M.B.A.,
  Sr. VP, CFO & Treasurer
• Christopher Paul Simms,
  Sr. VP & Chief Commercial Officer
• David F. Carroll,
  Sr. VP, CFO & Treasurer
• Keith Westby M.B.A.,
  Sr. VP & COO
• Calvin Roberts,
  Independent Director
• Jane Henderson,
  Independent Director
• Adrienne Graves,
  Lead Independent Director
• Axel Bolte,
  Independent Director
• Kathy Galante,
  Vice President, Investor Relations and Corporate Communications
• Mark Blumenkranz,
  Director
• Abraham Scaria,
  Chief Scientific Officer
• Evelyn Harrison,
  Sr. VP & Chief Clinical Operations Officer
• Amy R. Sheehan,
  Sr. VP & Chief HR Officer
• Todd D.C. Anderman,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Dr. Xiao-Ping Dai Ph.D.,
  Chief Technical Officer
• Dr. Samir C. Patel,
  Co-Founder and Consultant
• Christopher Paul Simms,
  SVP, Chief Commercial Officer
• Christine Ann Miller,
  Director
• David E Redlick,
  Director
• Venture Capital Iv, L.P.Ver...,
  
• Anthony S Gibney,
  EVP, Chief Business Officer
• Pravin Dugel,
  President